Subcutaneous infusions are on the rise as medical technology advances and pharmaceutical companies learn more. Fitusiran, called technically as ALN-AT3, is an investigational small interfering RNA therapeutic injected subqutaneously to block antithrombin activity. Fitusiran is being developed and studied by Alnylam Pharmaceuticals, the co-developer of Fitusiran, along with Sanofi Genzyme. Antithrombin is a protein that prevents clotting. Fitusiran is aimed at significantly reducing bleeding and leading to meaningful improvement in health-related life quality.
Also Read - What Is HEMLIBRA?
A phase 3 study was presented at ASH which concluded that Fitusiran decreased the patients group's bleeding by over 90 percent, as compared with the patient group not on prophylaxis. Second to this is another benefit, the once a month injection. You can read more about Fitusiran here.
Want to learn more about bleeding disorders? Sign up for our newsletter here! SIGN UP
Comments